What is Parametrics Medical?
Founded in 2008, Parametrics Medical operates as a specialized provider of allograft solutions, with a primary focus on the sports medicine market. The company distinguishes itself through a diverse portfolio of processing methodologies, including its proprietary Coll-e-Strong electron beam technology, Lo-Rad low-dose gamma irradiation, and No-Rad aseptic processing. By sourcing all materials exclusively from United States-based donors and adhering to the stringent guidelines of the American Association of Tissue Banks (AATB), the firm ensures a high level of safety and efficacy.
The company's market position is defined by its commitment to surgeon-centric service and product availability. By offering a comprehensive range of preservation techniques, Parametrics Medical addresses the nuanced requirements of modern orthopedic procedures, effectively bridging the gap between donor tissue availability and clinical demand.
How much funding has Parametrics Medical raised?
Parametrics Medical has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Parametrics Medical
PPP
Public-Private Partnership
What's next for Parametrics Medical?
With this recent strategic investment, Parametrics Medical is poised to enter a new phase of growth, focusing on the optimization of its supply chain and the potential expansion of its product distribution networks. The company's roadmap likely involves scaling its processing capacity to accommodate the increasing volume of sports medicine interventions, while simultaneously investing in research and development to refine its existing allograft portfolio.
Furthermore, the firm is expected to leverage its late-stage funding to strengthen its market presence against larger industry incumbents. By maintaining its focus on AATB-accredited safety protocols and high-touch customer service, Parametrics Medical is well-positioned to capture additional market share, ensuring that its specialized tissue offerings remain a preferred choice for surgeons seeking reliable, high-performance biological solutions.
